Cart
sales@molnova.com
Home - Products - Metabolic Enzyme/Protease - Transferase - Ervogastat

Ervogastat

CAS No. 2186700-33-2

Ervogastat( PF-06865571 )

Catalog No. M23988 CAS No. 2186700-33-2

Ervogastat is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 318 In Stock
5MG 307 In Stock
10MG 512 In Stock
25MG 826 In Stock
50MG 1097 In Stock
100MG 1479 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Ervogastat
  • Note
    Research use only, not for human use.
  • Brief Description
    Ervogastat is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor.
  • Description
    Ervogastat is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor. Ervogastat reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    PF-06865571
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Transferase
  • Recptor
    DGAT2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2186700-33-2
  • Formula Weight
    407.42
  • Molecular Formula
    C21H21N5O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:120mg/ml(294.54mM, need ultrasonic)
  • SMILES
    O=C(C1=CN=C(C2=CC(OC3=NC=CC=C3OCC)=CN=C2)N=C1)N[C@@H]4COCC4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.PFIZER INVESTOR DAY FEATURES SIGNIFICANT NUMBER OF PIPELINE ADVANCES FOR COVID-19 PROGRAMS AND ACROSS NUMEROUS THERAPEUTIC AREAS
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Minodronic acid mono...

    Minodronic acid monohydrate?is an farnesyl diphosphate synthase inhibitor that acts as a bone resorption inhibitor.

  • FGTI-2734

    FGTI-2734 can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors.?

  • Eliglustat

    Eliglustat (Tartrate) inhibits?glucosylceramide synthase(GCS),thus reducing the load of glucosylceramide influx into the lysosome.

Sign In Join Free